Marion Leboyer

Professor of Psychiatry · University of Paris Est Créteil · company speakers →

Marion Leboyer, M.D., Ph.D. is Professor of Psychiatry at the University of Paris Est Créteil (UPEC) in France. She is vice-chair of the University-affiliated department of Psychiatry and Addictology (Hôpitaux Universitaires Mondor, Assistance-Publique-Hôpitaux de Paris, AP-HP). She runs the laboratory “Translational NeuroPsychiatry” (http://www.imrb.inserm.fr/equipes/m-leboyer-s-jamain/) which is part of Mondor Institute for Biomedical research (IMRB, Inserm U955). Since 2007, she is the executive director of a non-profit foundation, “Fondation FondaMental” ( www.fondation-fondamental.org ) created by the French Ministry of Research, to support research in Psychiatry. The network of 55 expert centers created and coordinated by Fondation FondaMental, has enabled since 2010 to build several large and deeply-phenotyped cohorts of patients followed longitudinally, allowing the construction of shared observational databases and biobanks (FondaMental Advanced Centers of Expertise, FACE). These networks have enabled multiple collaborations within different national and international research programs. Dr Leboyer is the principal investigator of several international and national research projects, including the French Program in Precision Psychiatry funded in 2022 by France 2030. Dr. Leboyer has authored or co-authored more than 1000 peer-reviewed international publications (H-index = 127) and is part of the highly cited researchers (Clarivate) since 2018. She received the Inserm Grand Prize https://presse.inserm.fr/en/inserm-2021-prizes-science-more-mobilized-than-ever-to-serve-health/44300/ She is general secretary of the ECNP (European college of Neuropsychopharmacology) and vice-president of the Immuno-psychiatry network of the ECNP. Her research efforts contributed to a better identification of genetic and environmental risk factors associated with major psychiatric disorders towards better understanding of causal mechanisms. In particular, she has contributed to the identification of associations of genetic vulnerability factors, of immune dysfunctions in major mood and psychotic disorders, but also of environmental risk factors, as well as brain imaging abnormalities. Her goal is to pave the way towards precision psychiatry (Cevoli et al, 2026, Kas et al, 2025) by identification of biomarkers signatures to enrich our current categorical diagnosis towards the development of mechanisms-based treatments. She has contributed to the discovery of the consequence of low-grade inflammation on auto-immune psychosis (Jezequel et al, 2017), on activation of Human Endogenous Retrovirus (Tamouza et al, 2021), on gut brain abnormalities and on mitochondria abnormalities associated with metabolic syndrome (Godin et al, 2014, Bernard et al, 2024, Zachos et al, 2024).

Is this you? Claim this profile →